Clinical Modality of Resistance and Subsequent Management of Patients with Advanced Non-small Cell Lung Cancer Failing Treatment with Osimertinib | |
Mu, Yuxin; Hao, Xuezhi; Yang, Ke; Ma, Di; Wang, Shouzheng; Xu, Ziyi; Li, Junling; Xing, Puyuan | |
2019 | |
卷号 | 14期号:3页码:335-342 |
ISSN号 | 1776-2596 |
DOI | 10.1007/s11523-019-00644-6 |
URL标识 | 查看原文 |
收录类别 | SCIE ; PUBMED |
内容类型 | 期刊论文 |
URI标识 | http://www.corc.org.cn/handle/1471x/6340696 |
专题 | 中国医学科学院 北京协和医学院 |
推荐引用方式 GB/T 7714 | Mu, Yuxin,Hao, Xuezhi,Yang, Ke,et al. Clinical Modality of Resistance and Subsequent Management of Patients with Advanced Non-small Cell Lung Cancer Failing Treatment with Osimertinib[J],2019,14(3):335-342. |
APA | Mu, Yuxin.,Hao, Xuezhi.,Yang, Ke.,Ma, Di.,Wang, Shouzheng.,...&Xing, Puyuan.(2019).Clinical Modality of Resistance and Subsequent Management of Patients with Advanced Non-small Cell Lung Cancer Failing Treatment with Osimertinib.,14(3),335-342. |
MLA | Mu, Yuxin,et al."Clinical Modality of Resistance and Subsequent Management of Patients with Advanced Non-small Cell Lung Cancer Failing Treatment with Osimertinib".14.3(2019):335-342. |
个性服务 |
查看访问统计 |
相关权益政策 |
暂无数据 |
收藏/分享 |
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论